卵巢癌的長期維持治療

Long-Term Maintenance or Consolidation of Epithelial Ovarian Cancer

李耀泰(Yiu-Tai Li) ； 陳福民(Fu-Min Chen) ； 沈仁達(Jenta Shen) ； 郭宗正(Tsung-Cheng Kuo)

《中華民國婦癌醫學雜誌》 2009年1期 (2009/04) Pp. 6-10

https://doi.org/10.7010/JGO.200904.0006

摘要

卵巢癌患者在診斷時多屬晚期，標準治療是在減積手術後，以paclitaxel和carboplatin或cisplatinum作6個療程的術後輔助性化學治療，有效率雖高，但最後大部份患者仍會復發，復發後治癒的機會渺茫，僅在延長生命。最近有些報告提出建議，對首次化學治療後達完全有效的患者，不妨以單一未使用過的有效藥物，作加強或維持治療，對延長生命及生活品質可能較佳，但仍需更多案例的證明。

關鍵字

卵巢癌 ； 化學治療 ； liposomal doxorubicin ； topotecan

並列摘要

Most patients with advanced ovarian cancer achieve a clinical complete remission after cytoreductive surgery and combination chemotherapy, usually with six cycles of paclitaxel together with carboplatin. Unfortunately, the majority of patients experience disease recurrence. Although second-line treatments provide effective palliation and may extend survival, they are not curative. Consequently, if an effective consolidation or maintenance therapy that would prevent recurrences after a clinical complete response, it could have a potentially greater impact in advanced ovarian cancer. Generally, maintenance therapies have focused on prolonged administration of single-agent chemotherapy or extended cycles of induction chemotherapy. Several reports have been shown to extend survival in patients with advanced ovarian cancer.

並列關鍵字

Ovarian cancer ； maintenance therapy ； liposomal doxorubicin ； topotecan